Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X:
“The VWF : GPIbM and VWF:RCo appear the most suitable assays for monitoring VWF activity in iTTP patients treatment with caplacizumab. The VWF:GPIbR have a limited ability to detect caplacizumab’s inhibition. The VWF:Ab assay is unsuitable for this purpose ”
Title: Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.
Authors: Paola Colpani, Luciano Baronciani, Ilaria Mancini, Cristina Novembrino, Anna Lecchi, Giovanna Cozzi, Pasqualina De Leo, Massimo Boscolo Anzoletti, Silvia La Marca, Marco Boscarino, Maria Teresa Pagliari, Andrea Artoni, Flora Peyvandi
Read the full article here.
Stay updated with Hemostasis Today.
-
Jun 1, 2026, 18:51Francesco Giurazza: New Publication on Glubran-2 in Acute Bleeding Patients with Coagulopathies
-
Jun 1, 2026, 18:50Donald Arnold is the Recipient of the Roberts Award – ISTH
-
Jun 1, 2026, 18:49Amirreza Jabbaripour Sarmadian: My First Paper as Corresponding Author on Upper Extremity DVT Following COVID-19 Vaccination
-
Jun 1, 2026, 18:49James P. Crowley: How Combining Vitamin D analogs with Chemotherapy Impacts Survival Outcomes
-
Jun 1, 2026, 18:42Debojyoti Chakraborty: Small But Meaningful Steps Toward A Gene Editing Trial For Sickle Cell Disease In India
-
Jun 1, 2026, 17:14Tiffany Gacel: What an Incredible Day With NBCA and The Red Bus Tour at Memorial at Gulfport?
-
Jun 1, 2026, 17:12Marie-Claire Kofi: Poster Highlights the Process of Establishing the Sickle Cell Transitions Policy Lab
-
Jun 1, 2026, 17:00Azusa Nagao: Organizing the Symposium on Women and Bleeding Disorders at JSTH Annual Meeting
-
Jun 1, 2026, 16:57Kuljeet Kaur: Approach to Anemia – More Than Just a Low Hemoglobin